Search

Author/Creator Ghanima, W.

11. S291: PHASE I/II STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: LONG-TERM FOLLOW-UP. (23rd June 2022)

Authors:
Kuter, D. J.; Efraim, M.; Kaplan, Z.; Mayer, J.; Choi, P.; Jansen, A. G.; McDonald, V.; Baker, R.; Bird, R.; Garg, M.; Gumulec, J.; Kostal, M.; Gernsheimer, T.; Ghanima, W.; Yao, M.; Daak, A.; Cooper, N.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
192
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

12. S292: SUSTAINED RESPONSE OFF TREATMENT IN ELTROMBOPAG-TREATED PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE STEROIDS: PRIMARY ANALYSIS OF THE PHASE II TAPER TRIAL. (23rd June 2022)

Authors:
Cooper, N.; Ghanima, W.; Vianelli, N.; Valcárcel, D.; Yavaşoğlu, I.; Melikyan, A.; Yañez Ruiz, E.; Haenig, J.; Lee, J.; Maier, J.; Zolkin, N.; Zaja, F.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
193
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗